The Global Market for HPV Testing is Projected to Reach US$511.8 Million by 2020
Rising Awareness Levels & Need for Early
Detection & Prevention to Fuel the Global HPV Testing Market, According to a
New Report by Global Industry Analysts,
Inc.
GIA
announces the release of a comprehensive global report on HPV Testing. The
global market for HPV Testing is projected to reach US$511.8 million by 2020,
driven by the rising prevalence of cervical cancer and the growing emphasis on
early detection.
Cervical
cancer is the second most prevalent form of cancer affecting women. Smoking,
early age coitarche, multiple sexual partners, and irregular screening are some
of the high-risk factors for cervical cancer. However, in most instances, the
disease is attributed to infection of genitals with human papilloma virus
(HPV). HPV generally causes infection in mouth, genitals, hands, and fingers. Increasing
awareness about the link between cervical cancer incidence and HPV, globally,
is driving the focus on HPV testing. The market also stands to benefit from the
development of advanced tests offering better detection capabilities.
While
pap smear testing has long been the widely used primary screening test for
cervical cancer diagnosis, lower test sensitivity, high level of false-negative
results, and inadequate follow up after positive test results are shifting the
focus onto HPV testing. Greater sensitivity and improved protection against
cervical cancer and high-grade cervical lesions compared to cytology-based
tests has led to HPV tests being used as a
primary cervical cancer screening test in several countries. The April 2014
approval of Roche’s cobas HPV Test by the US FDA for use as a first-line
primary screening tool for cervical cancer diagnosis in women aged 25 years and
older exemplifies the potential of HPV tests for primary screening purposes.
In
the coming years, the global HPV testing market is expected to make rapid
gains, driven by the rising incidence of cervical cancer across the world and
the growing emphasis on early detection and prevention. Increasing use of HPV
tests as a primary screening tool for cervical cancer in women older than 25
years, growing use of Pap/HPV co-testing for women aged 30 years and older, and
treatment guidelines in favor of HPV tests for screening even HPV vaccinated
women are other factors fuelling market growth. While vaccines have been
approved for screening in women up to 26 years, the vaccines offer protection
only against the highest risk HPV types. The fact that HPV vaccination does not
preclude female population from cervical cancer screening will continue to
drive sales of HPV tests even among vaccinated women.
As
stated by the new market research report on HPV Testing, the United States
represents the largest market worldwide. While penetration rates below 50% and recommendations
favoring longer co-testing intervals exert downward pressure on growth, rising incidence
of cervical cancer, and positive government efforts in organizing awareness,
screening, diagnosis and immunization programs, will spur growth. Also, the US
FDA’s approval of Roche’s cobas HPV test for primary screening will contribute to
growth in the market. Developing markets across Asia-Pacific and Latin America
are expected to grow at a relatively faster rate than the United States as over
80% of the new cases are reported annually in these markets. The greater
convenience associated with HPV testing compared to Pap smear tests will help spur
adoption in under-penetrated emerging markets.
Major
players covered in the report include Abbott Molecular Inc., Arbor Vita
Corporation, Becton, Dickinson and Company, DaAn Gene Co. Ltd., F. Hoffmann-La
Roche Ltd., Hologic Inc., QIAGEN N., and Seegene Inc.
Comments
Post a Comment